A phase II study (Peng et al. 2021) on RC48 in patients with advanced or metastatic HER2-positive GC or GEJA showed an ORR of 24.8% (95% CI = 17.5–33.3%), with a mPFS and mOS of 4.1 (95% CI = 3.7–4.9) months and 7.9 (95% CI = 6.7–9.9) months, respectively. The gene discussed is ERBB2; the disease is gastric cancer.